- Cellipont Bioservices has entered a collaboration with BobcatBio to manufacture RB-1355 for Phase I clinical trials.
- The agreement supports ongoing studies in solid tumors and lymphoma using a macrophage-based cell therapy approach.
Cellipont Bioservices has announced a strategic collaboration with BobcatBio to provide contract manufacturing support for RB-1355, a macrophage-based cell therapy currently in clinical development. Under the agreement, Cellipont will manufacture Phase I cell therapy products to support BobcatBio’s ongoing clinical trials in solid tumors and lymphoma.
RB-1355 is designed to use a patient’s macrophages to generate a targeted immune response against tumors. According to the companies, early clinical findings in relapsed or refractory non-Hodgkin lymphoma show that the therapy is well tolerated and has demonstrated early signs of activity. The therapy can also be administered without lymphodepleting chemotherapy and allows for multiple doses from a single apheresis through cryopreservation.
The collaboration focuses on enabling the advancement of RB-1355 through clinical development by leveraging Cellipont’s CDMO and contract manufacturing capabilities in cell therapy. The agreement supports the production of clinical-stage material required for ongoing trials.
“At Cellipont, we are committed to supporting innovators who are pushing the boundaries of what cell therapy can do for patients. BobcatBio’s work reflects the kind of bold science this field needs, and we are proud to support the advancement of a program with the potential to open new possibilities in solid tumors.”
Darren Head, CEO of Cellipont Bioservices
BobcatBio stated that the partnership is intended to ensure access to manufacturing expertise and infrastructure needed to advance its therapy. The collaboration highlights the role of specialized CDMOs in supporting the development of complex cell-based therapies for oncology indications.
